Medical/Pharmaceuticals Global News & Press Release Distribution

Aphranel Convenes Cadaver Dissection Class in Thailand Successfully

BANGKOK, Jan. 14, 2026 /PRNewswire/ -- The inaugural "Moyom Biotech • Aphranel Global Expert Advisory Panel • Thailand Anatomy Exchange Conference" was successfully convened inThailand. This high-level forum gathered leading experts from multipleAsia-Pacific countries. Through this concentrated ...

2026-01-15 17:51 5005

Aphranel Convenes Cadaver Dissection Class in Thailand Successfully

GCCL and OPIS Announce Strategic Collaboration to Advance Global Clinical Trial Capabilities

YONGIN, South Korea, Jan. 15, 2026 /PRNewswire/ -- GCCL, a leading South Korea -based provider of clinical trial sample analysis, and OPIS, a global full-service contract research organization (CRO), have signed a Memorandum of Understanding (MOU) on the sidelines of the 44th Annual J.P. Morgan He...

2026-01-15 15:31 7005

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

* Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects * 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients * Complex modalities are WuXi Biologics' core growth engi...

2026-01-15 12:00 8280

Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus

- UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as "The weapon to end the virus war." - Announces "One Drug, Two Tracks" strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the same drug. - Dr. Davey Smith: "With this multi-v...

2026-01-15 11:34 6952

Yuyu Pharma Establishes UCLA Office to Accelerate U.S. Pet Industry Expansion

SEOUL, South Korea, Jan. 14, 2026 /PRNewswire/ -- Yuyu Bio and Mervyn's Petcare, pet-focused subsidiaries of Yuyu Pharma, have opened a new office on theUCLA campus, strengthening the company's presence in the United States pet and animal health market. The two companies are now based at Magni...

2026-01-14 22:00 6892

Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

HONG KONG, Jan. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), comparing cadonilimab plus chemotherapy against a PD-1 inhibitor plus chemotherapy for th...

2026-01-14 11:54 6636

Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference

* Celltrion outlines a blueprint for innovative drug development built on its antibody expertise * The company highlights its business strategy to scale U.S. manufacturing and R&D capabilities, strengthening its global supply chain, production and operations INCHEON, South Korea, Jan. 13, 202...

2026-01-14 09:18 7257

Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS

NANTONG, China, Jan. 13, 2026 /PRNewswire/ -- Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral sclerosis (ALS). The initial dosing occurred at Second ...

2026-01-13 20:30 11263

Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ

SHANGHAI, Jan. 13, 2026 /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company advancing innovative CAR-T cell therapies for solid tumors, recently announced clinical data from its Phase I/IIa study of IMC002, a VHH-based anti-CLDN18.2 CAR-T therapy, in patients with advanced gastric ...

2026-01-13 16:26 10354

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have r...

2026-01-13 11:07 12690

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have r...

2026-01-13 11:07 9919

Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announcedtoday that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent small-molecule colony-...

2026-01-13 08:54 7273

Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announcedtoday that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent small-molecule colony-...

2026-01-13 08:54 11280

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

* AbbVie will provide low prices in Medicaid, and expand affordable, direct-to-patient offerings for treatments used by millions of Americans through TrumpRx * AbbVie will commit $100 billion in U.S. research and development (R&D) and capital investments, including manufacturing, over the nex...

2026-01-13 07:30 7089

Datasea Announces Major Acoustic Technology Advancements in Brain-Computer Interface Applications

Acoustic-Driven Technologies Poised to Support Embodied Intelligence and Health Robotics Applications in a Multi-Billion-Dollar Brain–Computer Interface Market BEIJING, Jan. 12, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company specializing in aco...

2026-01-12 22:30 9155

Deepson Bio Receives Presidential Award at 2025 Korea Invention Patent Exhibition

Award highlights promise of ultrasound-based innovation in addressing unmet needs in dementia treatment SEOUL, South Korea, Jan. 12, 2026 /PRNewswire/ -- Deepson Bio Co., Ltd., a medical technology company focused on ultrasound-based approaches to dementia treatment, was honored with the Preside...

2026-01-12 22:00 7124

Deepson Bio Receives Presidential Award at 2025 Korea Invention Patent Exhibition

LumiMind Wins SPEED AWARD at CES 2026 for Innovative Non-Invasive Sleep Technology With Real-Time EEG

LAS VEGAS, Jan. 12, 2026 /PRNewswire/ -- LumiMind, a next-generation neurotechnology company advancing non-invasive brain health solutions, today announced that it has won theSPEED AWARD at CES 2026 for its breakthrough consumer sleep technology,LumiSleep.

2026-01-12 22:00 7323

LumiMind Wins SPEED AWARD at CES 2026 for Innovative Non-Invasive Sleep Technology With Real-Time EEG

Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease

CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage, generative AI-driven drug discovery company, today announced the completion of first patient first dose in BETHESDA: a Phase IIa clinical trial of ISM5411 (NCT07265570

2026-01-12 21:30 7867

WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing

SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of PatroLabTM, a state-of-the-art digital twin platform designed to transform bioprocess development and manufactur...

2026-01-12 21:09 9871

CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

SHANGHAI, PHILADELPHIA and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, and Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveragin...

2026-01-12 21:05 9637